The launch marks a significant achievement for the Indian scientific community, moving from research and development to a high-accuracy, scalable and reliable test in less than 100 days Credit: Representational Image

Guwahati: The Drug Controller General of India (DCGI) on Saturday gave approval for the commercial launch of India’s first Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) coronavirus test ‘Feluda’, developed by the Tata Group and CSIR-IGIB (Institute of Genomics and Integrative Biology).

As per an official release issued Ministry of Science and Technology, The Tata CRISPR test, powered by CSIR-IGIB, received regulatory approvals from DCGI for commercial launch, as per ICMR guidelines, meeting high-quality benchmarks with 96% sensitivity and 98% specificity for detecting the novel coronavirus.

“This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus. CRISPR is a genome-editing technology to diagnosing diseases. The Tata CRISPR test is the world’s first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing Covid-19,” said the release.

The release further said that the launch marks a significant achievement for the Indian scientific community, moving from research and development to a high-accuracy, scalable and reliable test in less than 100 days.

“This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus. CRISPR is a genome-editing technology to diagnosing diseases. The Tata CRISPR test is the world’s first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing Covid-19,” said the release.

The release further said that the launch marks a significant achievement for the Indian scientific community, moving from research and development to a high-accuracy, scalable and reliable test in less than 100 days.

Anurag Agrawal, director, CSIR-IGIB, said the work started by CSIR under the sickle cell mission for genome diagnostics and therapeutics led to new knowledge that could be harnessed to quickly develop new diagnostic test for SARS-CoV-2.

According to the release, the group has worked closely with CSIR-IGIB and ICMR to create a high-quality test that will help the nation ramp up Covid-19 testing quickly and economically, with a ‘Made in India’ product that is safe, reliable, affordable, and accessible.



Latest Stories

Leave a comment

Leave a comment